Edgewell Personal Care reported Q2 FY2026 on May 6. The stock has fallen 25% in the nine sessions since, including -8.5% on May 15 with the consumer-staples cohort flat. The print materially improved the operational picture, not damaged it.

What the filing says

Q2 organic sales -240bps vs guidance -300bps. Adjusted EBITDA $73.8M. Adjusted EPS $0.60 vs $0.44 consensus (+36% surprise). Full-year guidance reaffirmed across every metric: organic -1% to +2%, gross margin +50bps, adj EPS $1.70-$2.10, EBITDA $245-$265M, FCF $80-$110M.

The signal buried in Q&A: U.S. Wet Shave category improved from -250bps in Q1 to -130bps in Q2. EPC overall share moved from -100bps to -10bps. Branded value share moved from -30bps to +40bps. CEO Rod Little disclosed 26 consecutive weeks of volume share growth — through April 2026 — under press from analysts asking about guidance confidence.

EPC's +40bps branded share gain in a -130bps category means EPC is taking share within a shrinking pie. The donor of that share is not identified by the filing. Three candidates: PG/Gillette (≈60-70% U.S. share), private label (Walmart Equate, ≈15-20%), or DTC erosion (Hims/Harry's competing for grooming wallet — though EPC owns Harry's). The PG Q4 FY2026 print is the disambiguator.

Other material disclosures:

• Hormuz oil exposure quantified at $3-5M FY2026, ≈$25M FY2027 pre-mitigation. EPC is the second consumer-staples mega-cap (after KMB) to put dollars on Middle East input-cost risk. Three Tier-3 peers (CL, CLX, PG) explicitly denied materiality in Q1 disclosures — a setup that reconciles on Q2 prints.
• FY2027 pricing lever named for the first time. 75% of portfolio addressable if oil stays elevated. Not in the Q1 call.
• Sun Care domestic category +17% YoY, EPC value share +180bps. Retail inventories described as lean.
• Cremo +38%. Grooming now >10% of business.
• Wet Shave plant consolidation Phase 1 "nearly complete." FY2026 is peak capex. FY2027 starts the savings flow; FY2028 full run-rate adds ≈2 pts of company gross margin.
• FY2027 FCF marker of $150M reinforced. CEO: "Second half ought to portend what's to come for 2027."

What the market thinks

Stock at $16.68. Market cap $834M. EV ≈$1.88B. EV/FY2026 EBITDA = 7.4x at guide midpoint.

FY2027 EBITDA is not management-guided. Inferring from the $150M FCF marker requires assumptions: actual FY2025 interest expense was $73M, FY2026 is peak capex with step-down ahead, tax rate ≈25%. Bridge: $150M FCF + $73M interest + $25-30M tax + $50-65M capex = $300-320M EBITDA range. EV/midpoint = ≈6.1x. Range 5.8-6.3x depending on interest paydown from FemCare proceeds and capex realization. Below distressed-tier comps (ENR/SPB ≈9-10x), well below mid-tier (KMB ≈13x, KVUE ≈14-15x), far below premium (CL/PG ≈17x, CHD ≈18x).

Forward P/E 7.87. Dividend yield 3.6%. Short interest 12.8% with 10.6 days to cover. RSI 19. Stock sits 6% off the 52-week low.

Analyst targets $21-32, mean $24.50 (+47% from current). UBS initiated Neutral $23 one week after earnings — most cautious sell-side target still implies +26%.

Insider purchases Nov 11-13, 2025: CEO Rod Little 103,087 shares (≈$1.72M), CFO Weissman ≈$114K, two officers ≈$300K. Four insiders, three days, ≈$2.4M coordinated, at prices materially above current.

Why the gap exists

The market is pricing the Q1 narrative — wet shave secular decline, FemCare divestiture dilution, peak capex year, balance sheet leverage 3.3-3.5x. The Q2 print disclosed an operational inflection that has been compounding for six months (the 26-week share trend was already in place when insiders bought in November) but the headline-driven tape has not synthesized it. The 26-week data point appeared in Q&A, not the press release. Sell-side initiation was Neutral.

Factor regression over 1 year shows idiosyncratic variance share at 76% — at the Paleologo target floor. β to XLP is 1.32 (17% variance contribution); β to IWM is 0.49 (6%). Every alpha source — wet shave share, FemCare margin recovery, plant savings, FY2027 pricing optionality, Sun Care share — is idiosyncratic. The 2-year β to XLP was 1.05; the 1-year reading is 1.32, meaning EPC has been trading with the cohort more tightly recently. The cohort has been flat-to-strong while EPC sold off; the recent drawdown is deeper than the XLP beta alone explains.

The May 15 -8.5% drop on 1.8x volume with cohort flat is unexplained. Two hypotheses: (a) forced selling — small-cap consumer-staples crossover redemption, factor-fund deleveraging — uncorrelated to fundamentals; (b) specific bear catalyst not yet visible — a customer loss, supplier disclosure, or undisclosed note. Falsifiable test: volume normalizes within 5 sessions = (a); persistent elevated volume = (b). Tax-loss harvesting is not the explanation; the relevant tax year does not end here. The hypothesis matters for sizing — (a) makes the entry cleaner; (b) requires reassessment.

Forward EV

Six-month scenarios:

Probability-weighted EV: 0.25×60 + 0.40×20 + 0.25×−15 + 0.10×−32 = +15% + 8% − 3.75% − 3.2% = +16% over six months. σ of outcomes ≈30%. Six-month Sharpe ≈0.5 (annualized ≈0.75).

Bear-severe weighted at 10% reflects the unconfirmed seller diagnosis and balance sheet leverage at peak capex, not just the operational picture.

Market-implied probability of a positive outcome, inferred from multiple compression (6.1x vs cohort median 13x), is roughly 50%. Estimated P(positive) is 65%. The probability gap is ≈15 percentage points.

Risks (ranked)

1. May 15 drop diagnosis fails. If the drop is news-driven (specific bear note, undisclosed operational deterioration, customer concentration disclosure), the framing changes and the bear-severe probability rises. Binding on sizing past a starter position.
2. β_XLP trajectory. 2y β = 1.05; 1y β = 1.32. If next quarterly regression shows >1.5 or idio variance share <70%, the pure-idio framing degrades and the pair-trade math weakens.
3. FY2027 H1 gross margin compression before plant savings flow. CFO declined to quantify FY2027 GM baseline; Q4 FY2026 one-time tailwinds do not repeat.
4. Walmart / Costco private label pressure. Walmart Equate sits in the wet shave price gap EPC's Billy targets. Retailer leverage on a $1B-cap supplier is non-trivial.
5. Middle East tourism exposure to Sun Care H2. Modest, management-flagged. Hormuz $3-5M FY26 oil drag is in the guide.
6. FemCare TSA stranded-cost unwind through Feb 2028. TSA covers ≈75-80% of stranded costs; unwind pace is unconfirmed.

Catalysts

What would change our mind

• CEO or CFO Form 4 selling in the next 60 days. Thesis breaks.
• Q3 print missing organic guide by 150bps+ AND FY2026 guidance cut.
• 8-K disclosing material customer loss (Walmart, Costco, Target shelf cuts).
• Next quarterly regression showing β_XLP > 1.5 OR idio variance share < 70%.
• PG Q4 FY2026 print showing clean U.S. wet shave recovery without Gillette weakness. Would imply the share gain came from private label or DTC, not PG — pair-trade thesis weakens though the long EPC case survives.
• May 15 drop diagnosed as news-driven within 5-10 sessions.

Trade structure note

An EPC/PG pair captures the wet shave share-rotation thesis directly and hedges ≈76% of XLP exposure passively. PG decomposition (1y): β_XLP = 1.00, idio variance share = 46%, σ_idio = 12%. The pair concentrates the thesis in the share-donor question — if PG is the donor, both legs work; if private label is the donor, the EPC thesis survives but the short leg is wasted capital. A long-only position in EPC carries XLP beta at ≈1.32x notional without an offsetting short.

Evidence